A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)

Starting soon

Conditions studied: SAR

In brief

This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.

Key facts

Study ID

NCT07459556

Run by

Chengdu Kangnuoxing Biopharma,Inc.

People needed

400

Starts

2026-03-01

Expected to finish

2028-02-01

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.
• Physician decision to treat the participant with Stapokibart Injection for SAR (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.

You may not qualify if…

• Known history of allergic reaction to Stapokibart Injection.
• Participants currently or plan participating in any interventional clinical trial.
• Participants with hematologic malignancies.
• Women with pregnant.
• Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.

Where it is running

• Beijing Tongren Hospital, CMU — Beijing, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.